A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting

Yang Liu,1–3 Dan Li,2 Xinhong Guo,2 Haiwei Xu,2 Zhi Li,2 Yanling Zhang,2 Chuanjun Song,4 Ruhan Fan,2 Xing Tang,1,* Zhenzhong Zhang2,* 1Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 2Department of Pharmaceutics, School of Pharmaceutical Scie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu Y, Li D, Guo X, Xu H, Li Z, Zhang Y, Song C, Fan R, Tang X, Zhang Z
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	10-hydroxycamptothecin conjugate controlled release; prodrug Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/789eeec6f2714fe1b9f7fab26b0f9b2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:789eeec6f2714fe1b9f7fab26b0f9b2a
record_format	dspace
spelling	oai:doaj.org-article:789eeec6f2714fe1b9f7fab26b0f9b2a2021-12-02T00:07:19ZA pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting1178-2013https://doaj.org/article/789eeec6f2714fe1b9f7fab26b0f9b2a2017-03-01T00:00:00Zhttps://www.dovepress.com/a-ph-responsive-prodrug-delivery-system-of-10-hcpt-for-controlled-rele-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yang Liu,1–3 Dan Li,2 Xinhong Guo,2 Haiwei Xu,2 Zhi Li,2 Yanling Zhang,2 Chuanjun Song,4 Ruhan Fan,2 Xing Tang,1,* Zhenzhong Zhang2,* 1Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 3Department of Pharmaceutics, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan, Zhengzhou, 4Department of Organic Chemistry, College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, People’s Republic of China *These authors contributed equally to this work Abstract: We synthesized a pH-responsive conjugate of 10-hydroxycamptothecin-thiosemicarbazide-linear polyethylene glycol 2000 (PEG2000). The conjugate was confirmed by matrix-assisted laser desorption time of flight mass spectrometry, 1H NMR, and 13C NMR. The water solubility of the prodrug was increased by over 3,000 times; much longer body circulation time, higher tumor-targeting ability, and reduced toxicity were observed, compared with commercial 10-HCPT injection. The linker contains a pH-sensitive hydrazone bond, which breaks under low pH conditions in the tumor microenvironment. The conjugates showed good stability in phosphate-buffered saline (pH 7.4) and rat plasma. This amphiphilic conjugate could self-assemble into nanosized micelles of 80–100 nm. Cytotoxicity assay results indicate significantly higher efficacy of the conjugate (IC50 [half maximal inhibitory concentration] =0.117 µM on SW180 cells) than 10-HCPT solution (IC50 =0.241 µM on SW480 cells). Cellular uptake analysis suggested its rapid internalization and nuclear transport. Pharmacokinetic analysis of the conjugates demonstrated that the conjugate circulated for a longer time in the blood circulation system (T2/1 =10.516±1.158 h) than did 10-HCPT solution (T2/1 =1.859±1.385 h), and that it also enhanced the targeting and mean residence time (MRT0–inf =39.873±4.549 h) in the tumor site, compared with 10-HCPT (MRT0–inf =9.247±1.026 h). Finally, the conjugate demonstrated an increased tumor growth inhibition effect (TIR =82.66%±7.175%) in vivo and lower side effects than 10-HCPT (TIR =63.85%±5.233%). This prodrug holds great promise in improving therapeutic efficacy and overcoming multidrug resistance. Keywords: 10-hydroxycamptothecin, conjugate, controlled release, prodrug, pH-responsive, hydrazoneLiu YLi DGuo XXu HLi ZZhang YSong CFan RTang XZhang ZDove Medical Pressarticle10-hydroxycamptothecinconjugatecontrolled release;prodrugMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 2227-2242 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	10-hydroxycamptothecin conjugate controlled release; prodrug Medicine (General) R5-920
spellingShingle	10-hydroxycamptothecin conjugate controlled release; prodrug Medicine (General) R5-920 Liu Y Li D Guo X Xu H Li Z Zhang Y Song C Fan R Tang X Zhang Z A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
description	Yang Liu,1–3 Dan Li,2 Xinhong Guo,2 Haiwei Xu,2 Zhi Li,2 Yanling Zhang,2 Chuanjun Song,4 Ruhan Fan,2 Xing Tang,1,* Zhenzhong Zhang2,* 1Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 3Department of Pharmaceutics, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan, Zhengzhou, 4Department of Organic Chemistry, College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, People’s Republic of China *These authors contributed equally to this work Abstract: We synthesized a pH-responsive conjugate of 10-hydroxycamptothecin-thiosemicarbazide-linear polyethylene glycol 2000 (PEG2000). The conjugate was confirmed by matrix-assisted laser desorption time of flight mass spectrometry, 1H NMR, and 13C NMR. The water solubility of the prodrug was increased by over 3,000 times; much longer body circulation time, higher tumor-targeting ability, and reduced toxicity were observed, compared with commercial 10-HCPT injection. The linker contains a pH-sensitive hydrazone bond, which breaks under low pH conditions in the tumor microenvironment. The conjugates showed good stability in phosphate-buffered saline (pH 7.4) and rat plasma. This amphiphilic conjugate could self-assemble into nanosized micelles of 80–100 nm. Cytotoxicity assay results indicate significantly higher efficacy of the conjugate (IC50 [half maximal inhibitory concentration] =0.117 µM on SW180 cells) than 10-HCPT solution (IC50 =0.241 µM on SW480 cells). Cellular uptake analysis suggested its rapid internalization and nuclear transport. Pharmacokinetic analysis of the conjugates demonstrated that the conjugate circulated for a longer time in the blood circulation system (T2/1 =10.516±1.158 h) than did 10-HCPT solution (T2/1 =1.859±1.385 h), and that it also enhanced the targeting and mean residence time (MRT0–inf =39.873±4.549 h) in the tumor site, compared with 10-HCPT (MRT0–inf =9.247±1.026 h). Finally, the conjugate demonstrated an increased tumor growth inhibition effect (TIR =82.66%±7.175%) in vivo and lower side effects than 10-HCPT (TIR =63.85%±5.233%). This prodrug holds great promise in improving therapeutic efficacy and overcoming multidrug resistance. Keywords: 10-hydroxycamptothecin, conjugate, controlled release, prodrug, pH-responsive, hydrazone
format	article
author	Liu Y Li D Guo X Xu H Li Z Zhang Y Song C Fan R Tang X Zhang Z
author_facet	Liu Y Li D Guo X Xu H Li Z Zhang Y Song C Fan R Tang X Zhang Z
author_sort	Liu Y
title	A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
title_short	A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
title_full	A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
title_fullStr	A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
title_full_unstemmed	A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting
title_sort	ph-responsive prodrug delivery system of 10-hcpt for controlled release and tumor targeting
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/789eeec6f2714fe1b9f7fab26b0f9b2a
work_keys_str_mv	AT liuy aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT lid aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT guox aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT xuh aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT liz aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT zhangy aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT songc aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT fanr aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT tangx aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT zhangz aphresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT liuy phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT lid phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT guox phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT xuh phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT liz phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT zhangy phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT songc phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT fanr phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT tangx phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting AT zhangz phresponsiveprodrugdeliverysystemof10hcptforcontrolledreleaseandtumortargeting
_version_	1718403936078004224

A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting

Ejemplares similares